International Journal of Hematology

, Volume 90, Issue 3, pp 413–415 | Cite as

Cord blood transplantation with a reduced-intensity conditioning regimen for patients with relapsed aggressive multiple myeloma after cytoreduction with bortezomib

  • Ikumi Kasahara
  • Mitsufumi Nishio
  • Satoshi Yamamoto
  • Tomoyuki Endo
  • Katsuya Fujimoto
  • Keisuke Yamaguchi
  • Yukari Takeda
  • Hideki Goto
  • Norihiro Sato
  • Takao Koike
Case Report

Abstract

Two multiple myeloma patients relapsed after autologous stem cell transplantation (ASCT). Conventional chemotherapy, including thalidomide, showed very little effect, but both patients responded well to a standard dose of bortezomib. One patient was treated with two additional cycles of bortezomib, but his clinical course suddenly deteriorated. Unrelated cord blood transplantation (CBT) with reduced-intensity conditioning regimen (RIC) was performed in refractory disease. After CBT, the clinical course was aggravated by tumor lysis syndrome and other conditions, thus resulting in patient death on day 34. Thereafter, we administered CBT with RIC on the second patient after just one course of bortezomib therapy since she was in partial remission. The second patient developed acute and chronic GVHD, and both responded to the steroid therapy. She has been in complete remission for more than 48 months after CBT. These results suggested that the timing of CBT with RIC may be very important, and cytoreduction with not only ASCT but also bortezomib could give a promising chance for a successful CBT.

Keywords

Cord blood transplantation Aggressive myeloma Bortezomib 

Notes

Acknowledgment

We thank Brian Quinn for language assistance.

References

  1. 1.
    Barlogie B. Diagnosis and treatment of high-grade myeloma. Am J Med. 1990;88:445–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Tricot G, Vesole DH, Jagannath S, Hilton J, et al. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87:1196–8.PubMedGoogle Scholar
  3. 3.
    Harris DT. In vitro and in vivo assessment of the graft-versus-leukemia activity of cord blood. Bone Marrow Transpl. 1995;15:17–23.Google Scholar
  4. 4.
    Howrey RP, Martin PL, Driscoll T, Szabolcs P, Kelly T, Shpall EJ, et al. Graft-versus-leukemia-induced complete remission following unrelated umbilical cord blood transplantation for acute leukemia. Bone Marrow Transpl. 2000;26:1251–4.CrossRefGoogle Scholar
  5. 5.
    Kishi Y, Kami M, Miyakoshi S, et al. Early immune reaction after reduced-intensity cord-blood transplantation for adult patients. Transplantation. 2005;80:34–40.CrossRefPubMedGoogle Scholar
  6. 6.
    Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood. 2005;105:4532–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Lekakis L, Giralt S, Couriel D, et al. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transpl. 2006;38:421–6.CrossRefGoogle Scholar
  8. 8.
    Yamada T, Tomonari A, Takahashi S, et al. Unrelated cord blood transplantation with a reduced-intensity conditioning regimen following autologous transplantation for multiple myeloma. Int J Hematol. 2004;80:377–80.CrossRefPubMedGoogle Scholar
  9. 9.
    Miura Y, Azuma T, Kusumi E, et al. Graft-versus-myeloma effects in reduced-intensity cord blood transplantation. Int J Hematol. 2007;86:463–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–17.CrossRefPubMedGoogle Scholar
  11. 11.
    Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165–72.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2009

Authors and Affiliations

  • Ikumi Kasahara
    • 1
  • Mitsufumi Nishio
    • 1
  • Satoshi Yamamoto
    • 1
  • Tomoyuki Endo
    • 1
  • Katsuya Fujimoto
    • 1
  • Keisuke Yamaguchi
    • 1
  • Yukari Takeda
    • 1
    • 2
  • Hideki Goto
    • 1
  • Norihiro Sato
    • 2
  • Takao Koike
    • 1
  1. 1.Department of Medicine IIHokkaido University Graduate School of MedicineSapporoJapan
  2. 2.Translational Research and Clinical Trial CenterHokkaido University HospitalSapporoJapan

Personalised recommendations